小细胞肺癌新药物研究进展

Advances in drug treatment of small cell lung cancer

小细胞肺癌约占肺癌的15％～20％，具有增殖快、转移早等特点。尽管其对放、化疗比较敏感，但几十年来的临床试验并没能找到彻底治愈SCLC的有效方法，EP／EC方案依旧是SCLC的标准一线化疗方案，多数患者在一线治疗以后仍会复发或转移。针对SCLC的新的化疗药物和生物靶向治疗药物的正在研究之中，这些药物为SCLC的治疗带来新的希望。

Small cell lung cancer（SCLC）,characterized by rapid growth and early metastasis,accounts for about 15%-20% of all lung cancer. Although SCLC is an chemosensitive and radiosensitive disease, but decades of research investigating multimodality treatments have failed to control or cure this disease in most patients. The combination of etoposide/cisplatin or etoposide/carboplatin is the first line chemotherapy regimen. Some new type chemotherapeutics and targeted biology therapies for SCLC are now being investigated, these agents may provide hope for future treatment of SCLC,